Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Antineutrophil cytoplasmic autoantibody associated vasculitides has 3 different types: Granulomatosis with polyangiitis, eosinophilic granulomatosis and polyangiitis and microscopic polyangiitis. These vasculitides manifest differently based on which area of small and medium size vessels in our bodies that it affects. In this case report, we discuss a unique case of microscopic polyangiitis diagnosed in a 75-year-old male who was relatively asymptomatic i.e. indolent, apart from nodules present in the lung with the use of the diagnostic criteria outlined by 2022 American College of Rheumatology and European Alliance of Associations for Rheumatology. In addition, we reviewed briefly about vasculitis, its epidemiology and the workup of microscopic polyangiitis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10754038 | PMC |
| http://dx.doi.org/10.22551/2023.41.1004.10276 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world outcomes of rituximab- and cyclophosphamide-based induction therapy regimens alone and in combination over 24 months in ANCA-associated vasculitis.
Clin Exp Rheumatol
September 2025
Department of Rheumatology and Clinical Immunology, University of Lübeck, Germany.
Objectives: This retrospective cohort study aimed to evaluate real-world data on the efficacy of rituximab (RTX) alone versus combined rituximab/cyclophosphamide (RTX/CYC) induction therapy, followed by RTX maintenance, compared with cyclophosphamide-azathioprine (CYC-AZA) therapy in ANCA-associated vasculitis (AAV).
Methods: Patients with new-onset or relapsing organ- or life-threatening AAV (granulomatosis with polyangiitis [GPA] n=97; microscopic polyangiitis [MPA], n=69) were followed over 24-months. Patients with previous RTX and/or CYC therapy were excluded.
Efficacy and safety of rituximab and low dosage of glucocorticoids for ANCA associated vasculitis interstitial lung disease: a proof-of-concept study.
Respir Med
August 2025
Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy.
Introduction: The prevalence of interstitial lung disease (ILD) in ANCA associated vasculitis (AAV) ranges from 13 % to 45 %, and both its definition and management represent a quandary. The occurrence of lung fibrosis and ANCA positivity, particularly in subjects without any other evidence of vasculitis, is far from being clearly interpreted, as well as its proper therapeutic management. In this regard, aim of this study is to assess whether Rituximab (RTX) in association with a low dosage of glucocorticoids (GCs), could be effective also in the treatment of AAV-ILD.
View Article and Find Full Text PDF[Pulmonary manifestations of ANCA-associated vasculitis in imaging].
Radiologie (Heidelb)
August 2025
Institut für Radiologie, Radboud Universität, Nijmegen, Niederlande.
Clinical/methodical Issue: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) such as granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and microscopic polyangiitis (MPA) are rare autoimmune diseases that frequently involve the lungs and may present with life-threatening complications. Their differentiation can be challenging due to overlapping clinical and radiological findings.
Standard Radiological Methods: High-resolution computed tomography (HRCT) is the key imaging modality for detecting pulmonary changes such as nodules, ground-glass opacities, and consolidations.
Current Overview of Multi-omics Analyses in Microscopic Polyangiitis and Granulomatosis with Polyangiitis.
Intern Med
August 2025
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Japan.
Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is an autoimmune disease characterized by autoantibodies against neutrophil cytoplasmic antigens such as myeloperoxidase (MPO) and proteinase 3 (PR3). AAV affects small blood vessels, leading to systemic inflammation and multiorgan damage. Recent advances in multi-omics analyses, including genomics, epigenomics, transcriptomics, proteomics, and metabolomics, have significantly improved our understanding of AAV complex pathophysiology.
View Article and Find Full Text PDFDiffuse pulmonary lesions caused by ANCA-associated vasculitis: A case report.
Medicine (Baltimore)
August 2025
Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China.
Rationale: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) encompasses rare, multisystem autoimmune diseases such as granulomatosis with polyangiitis (GPA), microscopic polyangiitis, and eosinophilic GPA. This group of vasculitides can manifest at any age, affecting various organ systems, with a notable frequency of respiratory involvement in GPA and microscopic polyangiitis. Pulmonary symptoms, often similar to those of respiratory infections, frequently complicate the diagnosis.
View Article and Find Full Text PDF